FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS

Adams, RA, Brown, E, Brown, L et al. (13 more authors) (2016) FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen. Oxford University Publishing .

Abstract

Metadata

Authors/Creators:
Keywords: FOCUS4
Dates:
  • Accepted: 15 July 2016
  • Published (online): 11 October 2016
  • Published: 11 October 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 11 Dec 2018 09:18
Last Modified: 14 Feb 2019 12:40
Status: Published
Publisher: Oxford University Publishing
Identification Number: https://doi.org/10.1093/annonc/mdw370.57

Share / Export

Statistics